BioSpace News Archive

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference.

It is with profound sadness that Coherus BioSciences, Inc. announces the passing of board member Samuel Nussbaum, M.D. During his distinguished career, Dr. Nussbaum worked as a physician, researcher, professor, and healthcare executive.

ANP Technologies, Inc. (ANP) announced the termination of the binding acquisition Term Sheet with Sorrento Therapeutics, Inc. (SRNE), effective September 28, 2021.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to treat COVID-19 in infected high-risk non-hospitalized patients (outpatients).

Codagenix, Inc., a clinical-stage biotechnology company pioneering a novel platform for vaccines and oncolytic virus therapies, today presented data from ongoing studies of their novel intranasal COVID-19 vaccine, COVI-VAC, at the IDWeek 2021 annual conference held virtually September 29-October 3.

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient has been successfully treated with its ViperCross peripheral support catheter.

Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the publication of results from a ground-breaking global genetic study in the New England Journal of Medicine, including findings of a potential treatment of structural birth defects caused by specific gene alterations.

Conformis, Inc. announced the strong results of a published retrospective study of procedures using Conformis’ patient-specific iTotal® CR knee replacement implant, which assessed implant survivorship, patient satisfaction, and functional outcomes.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.

GenFleet Therapeutics, and Innovent Biologics (HKEX: 01801) today announced that the first patient with KRAS G12C mutation has been dosed in the first-in-human trial of GFH925 (ClinicalTrials.gov, NCT05005234).